NewAmsterdam Pharma Company N.V. Warrant (NAMSW) Stock Price
NAMSWStock
$16.51+243.61%52W
Market Cap—
P/E—
PEG Ratio—
Div yield—
Beta6.92
NAMSW Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-47.73%
Price vs S&P 500 (4W)-25.95%
VGM Score55.32
Industry Peers — Pharmaceuticals(570)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
NAMSWNewAmsterdam Pharma Company N.V. Warrant | — | — | C | $16.51 |
| LLYEli Lilly & Co. | D | B | C | $1174.61 |
| JNJJohnson & Johnson | D | C | B | $268.04 |
| ABBVABBVIE INC. | D | C | B | $255.48 |
| MRKMerck & Co., Inc. | D | C | B | $148.35 |
| NVSNovartis AG | C | C | C | $153.81 |
| AZNAstraZeneca PLC | C | B | C | $162.70 |
| NVONovo-Nordisk A/S | B | C | C | $45.61 |
| ABTAbbott Laboratories | C | C | C | $112.47 |
| PFEPfizer Inc. | C | D | B | $27.96 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $541.69 |
About NewAmsterdam Pharma Company N.V. Warrant
NewAmsterdam Pharma is a late-stage biopharmaceutical company developing therapies for cardio-metabolic diseases. Its lead product, obicetrapib, is an oral CETP inhibitor designed to overcome the efficacy and tolerability limitations of current LDL cholesterol-lowering treatments in patients with inadequate response or poor tolerance to existing therapies.